Cargando…

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

BACKGROUND: Bcl-2 is positively regulated by hormonal receptor pathways in breast cancer. A study was conducted to assess the prognostic significances of clinico-pathologic variables and of ER, PR, p53, c-erbB2, bcl-2, or Ki-67 as markers of relapse in breast cancer patients who had received the ide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Kyung-Hun, Im, Seock-Ah, Oh, Do-Youn, Lee, Se-Hoon, Chie, Eui Kyu, Han, Wonshik, Kim, Dong-Wan, Kim, Tae-You, Park, In Ae, Noh, Dong-Young, Heo, Dae Seog, Ha, Sung Whan, Bang, Yung-Jue
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1863427/ https://www.ncbi.nlm.nih.gov/pubmed/17430582 http://dx.doi.org/10.1186/1471-2407-7-63

Ejemplares similares

Prognostic Value of p53 and bcl-2 Expression in Patients Treated with Breast Conservative Therapy
por: Kim, Kyubo, et al.
Publicado: (2010)

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
por: Keam, Bhumsuk, et al.
Publicado: (2007)

Effect of Time Interval between Breast-Conserving Surgery and Radiation Therapy on Outcomes of Node-Positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide Followed by Taxane
por: Koh, Hyeon Kang, et al.
Publicado: (2016)

A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions
por: Kim, Tae-Yong, et al.
Publicado: (2014)

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
por: Keam, Bhumsuk, et al.
Publicado: (2011)

Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data
por: Lee, Kyung-Hun, et al.
Publicado: (2012)

ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy
por: Kim, Hee-Jun, et al.
Publicado: (2015)

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
por: Rhee, Jiyoung, et al.
Publicado: (2008)

Phase II Study of Low-dose Paclitaxel and Cisplatin as a Second-line Therapy after 5-Fluorouracil/Platinum Chemotherapy in Gastric Cancer
por: Lee, Keun-Wook, et al.
Publicado: (2007)

Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Kim, Taeryung, et al.
Publicado: (2015)

Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less
por: Kwon, Ji Hyun, et al.
Publicado: (2010)

Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Chang, Ji Hyun, et al.
Publicado: (2016)

Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response
por: Lee, Ho-chang, et al.
Publicado: (2013)

A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer
por: Lee, Hyun Jung, et al.
Publicado: (2014)

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
por: Kim, Mi-Jung, et al.
Publicado: (2008)

Impact of Multimodality Approach for Patients with Leptomeningeal Metastases from Solid Tumors
por: Kwon, Jeanny, et al.
Publicado: (2014)

Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study
por: Vaz-Luis, Ines, et al.
Publicado: (2020)

Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study
por: Lim, Kyu-Hyoung, et al.
Publicado: (2009)

Diagnostic performance of contrast enhanced CT and (18)F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection
por: Lee, Yun-Gyoo, et al.
Publicado: (2011)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2021)

Adenoid Cystic Carcinoma of the Breast: A Case Series of Six Patients and Literature Review
por: Kim, Miso, et al.
Publicado: (2014)

Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
por: Lim, Kyu-Hyoung, et al.
Publicado: (2010)

Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study
por: Choi, Younak, et al.
Publicado: (2016)

Anticancer Drugs Paclitaxel, Carboplatin, Doxorubicin, and Cyclophosphamide Alter the Biophysical Characteristics of Red Blood Cells, In Vitro
por: Skverchinskaya, Elisaveta, et al.
Publicado: (2023)

Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2010)

Accelerated whole breast irradiation in early breast cancer patients with adverse prognostic features
por: Lee, Sea-Won, et al.
Publicado: (2016)

Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
por: Kim, Se Hyun, et al.
Publicado: (2016)

Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
por: Kim, Su-Jung, et al.
Publicado: (2010)

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2022)

A Comparative Study of Daily 3-Gy Hypofractionated and 1.8-Gy Conventional Breast Irradiation in Early-Stage Breast Cancer
por: Lee, Sea-Won, et al.
Publicado: (2016)

Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
por: Han, Hye-Suk, et al.
Publicado: (2009)

Treatment outcome of ductal carcinoma in situ patients treated with postoperative radiation therapy
por: Lim, Yu Jin, et al.
Publicado: (2014)

Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
por: Kim, Suzy, et al.
Publicado: (2011)

A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy
por: Chen, Yanhua, et al.
Publicado: (2020)

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
por: Xu, Qiaoping, et al.
Publicado: (2021)

The role of PET/CT in detection of gastric cancer recurrence
por: Sim, Sung Hoon, et al.
Publicado: (2009)

Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
por: Keam, Bhumsuk, et al.
Publicado: (2011)

Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer
por: Hwang, Ki-Tae, et al.
Publicado: (2017)

High-dose Versus Low-dose Cyclophosphamide in Combination with G-CSF for Peripheral Blood Progenitor Cell Mobilization
por: Ahn, Jin Seok, et al.
Publicado: (2005)

Postoperative chemoradiotherapy in high risk locally advanced gastric cancer
por: Song, Sanghyuk, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1alous90g48ls8ln778o6i1bi1